Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Clotting Factor Plays Critical Roll in Tumor Angiogenesis

By LabMedica International staff writers
Posted on 10 Nov 2009
A variant form of the blood clotting protein "Tissue Factor" or TF has been identified as a key modulator of angiogenesis, and may serve as a target for chemotherapy aimed at denying tumors the increased blood supply they require for growth and metastasis.

Investigators at the University of Cincinnati (OH, USA) in collaboration with colleagues at Leiden University (The Netherlands) worked with a modified form of TF known as alternatively spliced Tissue Factor or asTF, which previously had been found to be present in high levels in specimens of human cervical cancer.

They reported in the October 29, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) that the molecular activity of asTF differed substantially from that of native TF. More...
The modified TF was shown to bind to surface molecules called integrins on endothelial cells, which induced signaling cascades that triggered angiogenesis. Integrins are receptors that mediate attachment between a cell and the tissues surrounding it, which may be other cells or the extracellular matrix (ECM). They also play a role in cell signaling and thereby define cellular shape, mobility, and regulate the cell cycle. Increased interaction between asTF and integrins resulted in increased cell adhesion, cell migration, and development of new blood vessels in both cellular and animal models.

"This is an important breakthrough in cancer research because we are able to draw a more complete molecular picture of how Tissue Factor contributes to cancer growth," explained contributing author Dr. Vladamir Bogdanov, professor of hematology at the University of Cincinnati. "This will help translate basic research into real-life for therapies targeted to stop angiogenesis."

"Our findings introduce a whole new way of studying how the Tissue Factor gene influences tissue formation process, including angiogenesis," said Dr. Bogdanov. "This is another level of understanding the molecular actions behind Tissue Factor."

The investigators anticipate that these studies will encourage development of new ways to target specific forms of Tissue Factor to stop cancerous cell growth while causing minimal impact on the body's capability to stop bleeding.

Related Links:
University of Cincinnati
Leiden University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.